^
4ms
Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment (clinicaltrials.gov)
P=N/A, N=12, Completed, Thomas Jefferson University | Recruiting --> Completed | N=20 --> 12 | Trial completion date: Mar 2023 --> Jun 2023 | Trial primary completion date: Mar 2022 --> Jun 2023
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
4ms
Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiotherapy for locally advanced maxillary sinus cancer (JCOG1212): Results of the efficacy confirmation phase in patients with T4aN0M0: RADPLAT for T4aN0M0 Maxillary Sinus Cancer. (PubMed, Int J Radiat Oncol Biol Phys)
We demonstrated that RADPLAT showed favorable results for patients with T4aN0M0 MS-SCCs compared with the historical control for 3yr OS in surgery, which was from an earlier period, and showed some specific toxicities. Therefore, RADPLAT, as well as surgery, can be regarded as a possible treatment option for these patients.
Journal • Metastases
|
PLAAT3 (Phospholipase A And Acyltransferase 3)
|
cisplatin
7ms
A Rare Case of Tubercular Osteomyelitis of Maxilla: A Case Report. (PubMed, Indian J Otolaryngol Head Neck Surg)
She underwent endoscopic debridement of sinuses and histopathological examination was suggestive of Koch's infection. Patient was further treated with antitubercular therapy and showed significant improvement at four weeks follow up.
Journal
8ms
Surgical approach analysis of endoscopic resection of juvenile nasopharyngeal angiofibroma (PubMed, Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi)
Endoscopic resection of nasopharyngeal fibroangioma is the main treatment method for JNA. Selecting suitable endoscopic approach to resect JNA, To maximize the advantage of nasal endoscopic equipment according to the inherent anatomical space of the human nasal cavity, In order to achieve the purpose of JNA resection, reduce intraoperative and postoperative complications, reduce the recurrence rate and improve the prognosis.
Journal
9ms
Role of Elective Neck Dissection in Prognosis of N0M0 Maxillary Sinus Squamous Cell Carcinoma: Insights from SEER Database Analysis. (PubMed, J Stomatol Oral Maxillofac Surg)
Our findings suggest that END provides a survival benefit for N0M0 MSSCC patients. Additionally, a lymph node count greater than 5 in END is associated with improved staging accuracy and better prognosis. Prospective research is needed to validate these findings and inform clinical decision-making for N0M0 MSSCC patients.
Journal
9ms
Journal • MRI
9ms
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy (clinicaltrials.gov)
P2, N=93, Recruiting, M.D. Anderson Cancer Center | Phase classification: P=N/A --> P2
Phase classification
10ms
Transoral versus transfacial surgical approach to maxillary tumors: evaluation of outcomes and perspectives. (PubMed, Int J Oral Maxillofac Surg)
A satisfactory resection was obtained in both groups, with the transoral cohort achieving a higher rate of clear oncological margins (positive margins: transoral group 3.7% versus transfacial group 6.8%, P = 0.389) and a significantly higher University of Washington Quality of Life score (mean 72.2 versus 67.8, P < 0.001). Even large and invasive tumors can be treated successfully with the transoral approach, avoiding unesthetic facial scars while still providing complete resection of the tumor.
Journal
10ms
Impact of Radiation Dose on Treatment of Maxillary Cancer With Superselective Intra-arterial Cisplatin With Radiotherapy. (PubMed, Anticancer Res)
IMRT can escalate radiation dose safely with acceptable toxicities. The total dose may have an impact on the local control rate in RADPLAT.
Journal
|
PLAAT3 (Phospholipase A And Acyltransferase 3)
|
cisplatin
10ms
Clinical • P2 data • Metastases
|
PLAAT3 (Phospholipase A And Acyltransferase 3)
10ms
A multi-institutional retrospective study of 340 cases of sinonasal malignant tumor. (PubMed, Auris Nasus Larynx)
For patients with MSSCC without lymph node metastasis, aggressive surgery on the primary tumor contributes to improved prognosis.
Retrospective data • Journal
1year
Impact of Clinical Factors and Treatments on SMARCB1 (INI-1)-Deficient Sinonasal Carcinoma. (PubMed, Otolaryngol Head Neck Surg)
In the largest single-institution study of SMARCB1-deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.
Journal
|
SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
over1year
A Pediatric Case of High-Grade Secretory Carcinoma of the Maxillary Sinus With ETV6::NTRK3 Gene Fusion, Therapeutic Implications, and Review of the Literature. (PubMed, Pediatr Dev Pathol)
SC have an overall favorable prognosis, but cases with high grade morphology have been described in adult population and are related to a more aggressive clinical course. We present a pediatric case of secretory carcinoma involving the maxillary sinus with high grade morphology, with a review of the literature of secretory carcinomas with high grade component.
Review • Journal
|
NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
|
NTRK3 fusion
almost2years
Ameloblastic Carcinoma of the Maxilla: A Rare Case Report and Review of Literature from 1948 to 2021. (PubMed, Int J Surg Pathol)
This histopathologic and molecular profile supported the diagnosis of ameloblastic carcinoma. There has been no evidence of disease recurrence or metastasis eleven months after the initial diagnosis.
Review • Journal
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MTAP (Methylthioadenosine Phosphorylase) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • KRT19 (Keratin 19)
|
BRAF wild-type
almost2years
NCI-2021-13901: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer (clinicaltrials.gov)
P1, N=36, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Jun 2026 | Trial primary completion date: Feb 2025 --> Jun 2026
Enrollment open • Trial completion date • Trial primary completion date
|
PTEN (Phosphatase and tensin homolog) • AKT1S1 (AKT1 Substrate 1)
|
cisplatin • ipatasertib (RG7440)
2years
The role of the WNT signaling pathway in the maxillary sinus squamous cell carcinoma. (PubMed, Med Oncol)
Our findings take attention to the dysregulations of the WNT signaling pathway that may support maxillary sinus carcinogenesis. The results will pave the way for further studies that investigate the therapy target potential of the WNT signaling pathway in this rare cancer.
Journal
|
BCL9 (BCL9 Transcription Coactivator)
2years
NCI-2021-13901: Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Stage III-IVB Head and Neck Cancer (clinicaltrials.gov)
P1, N=46, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Jan 2022 --> Apr 2022
Trial initiation date
|
PTEN (Phosphatase and tensin homolog) • AKT1S1 (AKT1 Substrate 1)
|
cisplatin • ipatasertib (RG7440)
2years
New P1 trial
|
PTEN (Phosphatase and tensin homolog) • AKT1S1 (AKT1 Substrate 1)
|
cisplatin • ipatasertib (RG7440)
over2years
Rare case of metastatic adenocarcinoma to the maxillary sinus. (PubMed, BMJ Case Rep)
The patient is undergoing chemoradiation therapy for palliation of his symptoms. Clinicians should be aware of this potentional site of metastatic disease and suspect the diagnosis in a timely manner to avoid delays in making a diagnosis.
Clinical • Journal
|
CDX2 (Caudal Type Homeobox 2) • MUC2 (Mucin 2)
over2years
Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report. (PubMed, Oral Oncol)
He received TPF regimen induction chemotherapy combined with anti-PD1 inhibitor and radiotherapy. The effect of treatment was good.
Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)